

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

NOTICE OF BOARD MEETING

A meeting of the board of directors (the “**Board**”) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) will be held on Tuesday, April 28, 2026 for the purpose of, among other matters, considering and approving the first quarterly results of the Company and its subsidiaries for the three months ended March 31, 2026 and its publication.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. LOU Boliang
Chairman

Beijing, the PRC
April 14, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors, Mr. Li Shing Chung Gilbert as employee representative Director, Mr. LI Jiaqing and Ms. Wan Xuan as non-executive Directors, and Ms. LI Lihua, Prof. Tsang King Fung and Mr. YU Jian as independent non-executive Directors.